Navigating Market Access Challenges in Europe

This technical report outlines the complexities involved in bringing new drug therapies to market in Europe, particularly within the European Union (EU) and its 27 member states. It describes the differences in the reimbursement landscape compared to the United States, emphasizing the role of Health Technology Assessments (HTAs) and individual price negotiations that can lead to longer timelines for drug launches. The report details how disparities in healthcare infrastructure across countries can result in significant delays, impacting patient access. It also discusses the need for improved access to rare and orphan disease products, noting that while the U.S. sees a higher percentage of rare disease drugs reaching the market, Europe faces economic challenges that hinder availability. Furthermore, the report presents emerging solutions aimed at improving access, including harmonizing HTA processes, implementing risk-sharing agreements, enhancing data integration, and advocating for better incentives for orphan drug providers. These strategies aim to promote health equity across the region.